ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections

December 22, 2014

ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference

December 4, 2014

ContraFect Submits Complete Response to IND Clinical Hold for CF-301

December 2, 2014

ContraFect Corporation Announces Third Quarter 2014 Results

November 14, 2014

ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment

October 9, 2014

ContraFect Corporation to Present at the 13th Annual BIO Investor Forum

September 30, 2014

ContraFect Corporation Expands Senior Management Team

September 24, 2014

ContraFect Corporation to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference

September 19, 2014

ContraFect Corporation's Universal Influenza Treatment Receives SBIR Funding

September 16, 2014

ContraFect Corporation Announces Separation of Units Sold in IPO

September 9, 2014

RSS
  • « Previous
  • 1...
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter